EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report

Shunsuke Omura, Keeya Sunata, Tetsuo Tani iD, Koyuru Uchibori, Shun Shinomiya, Saeko Takahashi iD

Respirology Case Reports · 2026-07 · 14 (7)

DOI: 10.1002/rcr2.70671 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 15.07.2026. Verfasst von Shunsuke Omura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine Tokyo Saiseikai Central Hospital Tokyo Japan. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase (ALK) fusion genes are detected in approximately 3%–5% of non‐small cell lung cancers (NSCLC). Alectinib and lorlatinib are ALK tyrosine kinase inhibitors with established efficacy; however, their adverse event profiles differ. We report a 61‐year‐old man with recurrent ALK‐positive lung adenocarcinoma who developed a grade 2 drug eruption consistent with fixed drug eruption during alectinib therapy. The rash resolved following drug discontinuation and corticosteroid treatment. Lorlatinib was subsequently initiated without recurrence of cutaneous toxicity. Apart from Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 dyslipidemia, no significant adverse events occurred, and partial response has been maintained for over 1 year. This case suggests that lorlatinib may be a feasible alternative in patients who develop cutaneous adverse reactions to alectinib, enabling continuation of targeted therapy.

Schlagwörter

Stichwörter der Autor:innen

ALK fusion geneAlectinibLorlatinibdrug eruptionnon‐small cell lung cancer

Autor:innen und Institutionen

  • Division of Pulmonary Medicine Tokyo Saiseikai Central Hospital Tokyo Japan.
  • Division of Pulmonary Medicine, Department of Medicine Keio University School of Medicine Tokyo Japan.

ORCID-Profile: Tetsuo Tani, Saeko Takahashi

Zitieren

APA

Omura, S., Sunata, K., Tani, T., Uchibori, K., Shinomiya, S., & Takahashi, S. (2026). Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report. Respirology Case Reports, 14(7). https://doi.org/10.1002/rcr2.70671

Vancouver

Omura S, Sunata K, Tani T, Uchibori K, Shinomiya S, Takahashi S. Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report. Respirology Case Reports. 2026;14(7). doi:10.1002/rcr2.70671

BibTeX
@article{Omura2026,
  author = {Omura, Shunsuke and Sunata, Keeya and Tani, Tetsuo and Uchibori, Koyuru and Shinomiya, Shun and Takahashi, Saeko},
  title = {Successful Introduction of Lorlatinib After Drug Eruption With Alectinib in ALK ‐Positive Lung Adenocarcinoma: A Case Report},
  journal = {Respirology Case Reports},
  year = {2026},
  volume = {14},
  number = {7},
  doi = {10.1002/rcr2.70671}
}
Kostenlos starten →